BMY beats Q3 estimates and raises full-year revenue guidance to $50 billion
FROM THE WIRE · FINANCE.YAHOO.COM
BMY Q3 deep dive: pipeline advances offset margin pressure as guidance shifts Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q3 2026 results beating Wall Street's revenue expectations , with sales up 6.9% year on year to $13.07 billion. The company expects…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA guidance raise from a large pharmaceutical group, relevant for the biotech sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third-quarter revenue was $13.07 billion, up 6.9% year on year.
- 02Non-GAAP EPS of $1.35 was 12.4% above analysts' consensus.
- 03Full-year revenue guidance rose to $50 billion from $49.5 billion.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets